This workshop of the Institute of Medicine's Forum on Emerging Infections set
out to learn from experience what has been done and what is needed for the public
and private sectors to collaborate effectively and productively for the health of
the public. The emphasis was on cooperation in those product areas where returns
from the market might be perceived as too small or too complicated by other factors
to compete in industrial portfolios with other demands for investment.
Quintessential examples of such products are vaccines, and in some instances
therapies, for the diseases of children, for malaria, and for HIV/AIDS. Each of
these offers lessons for attempts to deal systematically with emerging infectious
diseases. While there are differences between the public health requirements of
developing countries and industrialized countries, the growth of the middle class in
the former and the vulnerability of the latter to diseases once thought to reside
permanently “offshore” are doing much to narrow those
The primary study case for the workshop was the Children's Vaccine Initiative
(CVI), formally established in 1991 as the first comprehensive effort to yoke
public- and private-sector scientific advances to a global public health priority
through purposive intersectoral collaboration. The lessons learned from the CVI were
integrated at the workshop with other experience from disease-focused efforts,
notably malaria and HIV/AIDS. The purpose of this report was to integrate that
learning and the tasks it suggests as points of reference for further action.
Support for this project was provided by Centers for
Disease Control and Prevention, National Institute of Allergy and Infectious
Diseases/NIH, Veterans Administration, Department of State, Food and Drug
Administration, several private pharmaceutical companies, private foundations and
The views presented are those of the Institute of Medicine Forum on Emerging
Infections and are not necessarily those of the funding organizations.
NOTICE: The project that is the subject of this report was approved by the Governing
Board of the National Research Council, whose members are drawn from the councils of
the National Academy of Sciences, the National Academy of Engineering, and the
Institute of Medicine. The members of the committee responsible for the report were
chosen for their special competencies and with regard for appropriate balance.
© 1997, National Academy of